ACADIA Pharmaceuticals ACAD class action and settlement news

Opinion · Devil's advocate

Fact-check-o-meter

Acadia called a missed phase 2 primary endpoint "Phase 3 enabling"

Acadia's commercial reporting lines up with its 10-Q, and its non-GAAP comparisons are reconciled. The gap is in the Sept. 24 RADIANT release, whose headline and bullets lead with "phase 3 enabling" trends while the registered primary endpoint was missed and the supportive secondary result is nominal. A certified securities class action over an earlier dementia psychosis filing remains pending per the 10-Q.

1. Press release vs filing · weight high

   Headline frames a primary endpoint miss as phase 3 enabling

   The company said: "Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis (ADP)" source

   The record says: ClinicalTrials.gov lists a single primary outcome for the RADIANT master protocol: SAPS-H+D total score change from baseline "From baseline to Week 6". The release's own second bullet says the study "Narrowly missed primary endpoint of SAPS H+D (p=0.0603)", with a standardized effect size of 0.26 for 60 mg. source

   Our view: The release does disclose the miss, but only after a headline and lead bullet built on trends. Investors reading headlines alone would not learn that the primary endpoint was missed.

2. Science · weight high

   Support rests on a nominal secondary and one surviving dose

   The company said: "Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect" source

   The record says: The release gives the CGI-S-ADP result as "p=0.0077 (nominal)" and says "The 30 mg dose showed minimal improvement across endpoints compared to placebo." Acadia is "implementing amendments to the Phase 3 program, including removing the 30 mg dosage arm." The release gives no patient numbers. ClinicalTrials.gov describes three seamlessly enrolling substudies with an estimated 1,074 participants and primary completion in January 2028. source

   Our view: A nominal p value on a secondary endpoint after a primary miss is hypothesis generating, not confirmation. The phase 3 studies now test a single dose, and full data, including sample sizes, are due at CTAD in November.

3. Press release vs filing · weight low

   Nuplazid growth headline uses an adjusted base

   The company said: "Second quarter NUPLAZID GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis" source

   The record says: The body of the same release says GAAP Nuplazid sales were "up 9% compared to GAAP net product sales of $168 million for the second quarter of 2025", and it reconciles the adjusted figure to an IRA rebate accrual change. The 10-Q balance sheet shows the same $956 million cash and investments total ($385.0 million cash plus $571.5 million securities). source

   Our view: This is a small and fully reconciled difference. Financial messaging is otherwise consistent with the 10-Q.

4. Legal and disclosure record · weight medium

   Certified securities class action is still pending

   The record says: Note 9 of the 10-Q discloses City of Birmingham Relief Retirement Systems v. Acadia Pharmaceuticals, Inc., Case No. 21-cv-0762, filed April 19, 2021 in the U.S. District Court for the Southern District of California. The amended complaint "generally alleges" nondisclosure of "statistical and design deficiencies" in the pimavanserin dementia-related psychosis sNDA. The court certified a class on March 11, 2024, and a final pretrial conference was scheduled for Sept. 2, 2026. An opt-out suit (Alger Dynamic Opportunities Fund, Case No. 24-cv-00451) is also pending, and a derivative suit (Kanner et al v. Biggar et al., Case No. 23-cv-2293) has a proposed settlement with governance reforms and $1.5 million in fees paid by the insurer, subject to court approval. source

   Our view: These are allegations in complaints. The 10-Q says the company cannot predict the outcome, cannot estimate possible losses and has accrued only attorneys' fees incurred to date. The class action concerns an earlier sNDA for dementia-related psychosis.

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our right of reply.